Cytel Scientists Call for a “Statistician-First Workflow” to Optimize Drug Development
July 30, 2020
Adaptive trial designs within oncology are described by Cytel scientists, and address data, statistical, and commercial and scientific value of flexible adaptive designs. A “Holistic Approach” to program development is delineated, wherein development plans are not created study by study, but across phases.
To learn about the Holistic Approach to trial design, how to avoid design phase by phase, and other new methods to streamline oncology drug development, visit the blog to download a complimentary paper.
(Source: Cytel Blog, Accessed July 30, 2020)